| The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03773991 |
Recruitment Status : Terminated (Recruitment issues: Restrictions associated with the COVID-19 pandemic have made much of the research procedures unfeasible due to organizational and safety issues (for both staff and patient protection).) First Posted : December 12, 2018 Last Update Posted : November 16, 2020 |
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Chris McIntyre, Lawson Health Research Institute
Brief Summary:
Shortness of breath is very common among patients on dialysis for kidney failure; however, its causes are often not understood. This study will explore the lungs and the heart of these patients to determine the causes of shortness of breath. The amount of salt in the body tissues, which tends to accumulate in dialysis patients and can also cause shortness of breath, will also be measured. Machines that exploit magnetic resonance, ultrasound and x-rays to take images of the body interior will be employed; in addition, breathing tests, questionnaires and blood tests will also be used. 20 patients on dialysis will be recruited and have two visits: one at the beginning of the study and one year later to observe any changes in the lungs, heart and salt accumulation over time.
Dyspnea; Uremic End Stage Renal Disease Chronic Lung Disease Chronic Heart Disease Hemodialysis-Induced Symptom Sodium Excess | Diagnostic Test: Lung MRI Diagnostic Test: Sodium MRI Diagnostic Test: Chest CT Diagnostic Test: Echocardiography Diagnostic Test: Fractional Exhaled Nitric Oxide Diagnostic Test: Pulmonary Function Tests Diagnostic Test: Blood Sampling Diagnostic Test: Six-Minute Walk Test Diagnostic Test: Dyspnea Questionnaires |
Study Type : | Observational |
Actual Enrollment : | 7 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Multimodal Assessment of Dyspnea, Cardiopulmonary Structure and Function in Chronic Hemodialysis Patients |
Actual Study Start Date : | March 29, 2019 |
Actual Primary Completion Date : | February 25, 2020 |
Actual Study Completion Date : | February 25, 2020 |
Resource links provided by the National Library of Medicine
Maintenance Hemodialysis Patients Patients on chronic hemodialysis therapy due to end-stage renal disease.
| Diagnostic Test: Lung MRI Proton Lung Magnetic Resonance Imaging Diagnostic Test: Sodium MRI Sodium Soft Tissue Magnetic Resonance Imaging Diagnostic Test: Chest CT High-resolution Quantitative Chest CT Diagnostic Test: Echocardiography Transthoracic 2D Speckle-Tracking Echocardiography Diagnostic Test: Fractional Exhaled Nitric Oxide Fractional Exhaled Nitric Oxide testing Diagnostic Test: Pulmonary Function Tests Spirometry and Plethysmography Diagnostic Test: Blood Sampling Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins Diagnostic Test: Six-Minute Walk Test Six-Minute Walk Test Diagnostic Test: Dyspnea Questionnaires Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale |
Primary Outcome Measures :
- Baseline Modified Medical Research Council scale score. [ Time Frame: Baseline ]
Baseline dyspnea measured by Modified Medical Research Council scale. 0-4 from lowest (no dyspnea) to highest (most severe dyspnea).
- Baseline University of California, San Diego Shortness of Breath Questionnaire score.
[ Time Frame: Baseline ]
Baseline dyspnea measured by University of California, San Diego Shortness of Breath Questionnaire.
0-120 from lowest (no dyspnea) to highest (most severe dyspnea).
- Baseline pulmonary artery diameter. [ Time Frame: Baseline ]
Baseline pulmonary artery diameter (in millimeters) by chest Computed Tomography.
- Baseline lung total blood vessel volume. [ Time Frame: Baseline ]
Baseline lung total blood vessel volume in ml by chest Computed Tomography.
- Baseline lung total airway count. [ Time Frame: Baseline ]
Baseline lung total airway count by chest Computed Tomography.
- Baseline lung low attenuation area. [ Time Frame: Baseline ]
Baseline lung low attenuation area by chest Computed Tomography.
- Baseline lung water content. [ Time Frame: Baseline ]
Baseline lung water content in arbitrary units measured by proton Magnetic Resonance Imaging.
- Baseline soft tissue sodium content. [ Time Frame: Baseline ]
Baseline soft tissue sodium content in mmol/L measured by sodium Magnetic Resonance Imaging.
Secondary Outcome Measures :
- One year changes in Modified Medical Research Council scale score.
[ Time Frame: Baseline and one year ]
Comparison of dyspnea measured by Modified Medical Research Council scale at one year versus baseline.
0-4 from lowest (no dyspnea) to highest (most severe dyspnea).
- Correlation between baseline modified Medical Research Council scale score and one year morbidity. [ Time Frame: Baseline and one year ]
One year morbidity risk by modified Medical Research Council scale baseline score.
- Correlation between baseline modified Medical Research Council scale score and one year mortality. [ Time Frame: Baseline and one year ]
One year mortality risk by modified Medical Research Council scale baseline score.
- Correlation between modified Medical Research Council scale score and soft tissue sodium content. [ Time Frame: Baseline and one year ]
Correlation coefficient between soft tissue sodium content (mmol/L) and modified Medical Research Council scale score.
- Correlation between modified Medical Research Council scale score and pulmonary artery diameter. [ Time Frame: Baseline and one year ]
Correlation coefficient between modified Medical Research Council scale score and pulmonary artery diameter (in millimeters), measured by chest Computed Tomography.
- Correlation between modified Medical Research Council scale score and lung total blood
vessel volume. [ Time Frame: Baseline and one year ]
Correlation coefficient between modified Medical Research Council scale score and lung total blood vessel volume (in milliliters), measured by chest Computed Tomography.
- Correlation between modified Medical Research Council scale score and lung total airway count. [ Time Frame: Baseline and one year ]
Correlation coefficient between modified Medical Research Council scale score and lung total airway count, measured by chest Computed Tomography.
- Correlation between modified Medical Research Council scale score and lung low attenuation areas. [ Time Frame: Baseline and one year ]
Correlation coefficient between modified Medical Research Council scale score and lung low attenuation areas, measured by chest Computed Tomography.
- Correlation between modified Medical Research Council scale score and lung total water content.
[ Time Frame: Baseline and one year ]
Correlation coefficient between modified Medical Research Council scale score and lung total water content (in arbitrary units), measured by proton Magnetic Resonance Imaging.
- One year changes in University of California, San Diego Shortness of Breath Questionnaire score. [ Time Frame: Baseline and one year ]
Comparison of dyspnea measured by University of California, San Diego Shortness of Breath Questionnaire at one year versus baseline.
0-120 from lowest (no dyspnea) to highest (most severe dyspnea).
- Correlation between baseline University of California, San Diego Shortness of Breath Questionnaire score and one year morbidity. [ Time Frame: Baseline and one year ]
One year morbidity risk by University of California, San Diego Shortness of Breath Questionnaire baseline score.
- Correlation between baseline University
of California, San Diego Shortness of Breath Questionnaire score and one year mortality. [ Time Frame: Baseline and one year ]
One year mortality risk by University of California, San Diego Shortness of Breath Questionnaire baseline score.
- Correlation between University of California, San Diego Shortness of Breath Questionnaire score and pulmonary artery diameter. [ Time Frame: Baseline and one year ]
Correlation coefficient between University of California, San Diego Shortness of Breath Questionnaire score and pulmonary artery diameter (in millimeters), measured by chest Computed Tomography.
- Correlation between University of California, San Diego Shortness of Breath Questionnaire score and soft tissue sodium content. [ Time Frame: Baseline and one year ]
Correlation coefficient between soft tissue sodium content (mmol/L) and University of California, San Diego Shortness of Breath Questionnaire score.
- Correlation between University of California, San Diego Shortness of Breath Questionnaire score and lung total blood vessel volume. [ Time Frame: Baseline and one year ]
Correlation coefficient between University of California, San Diego Shortness of Breath Questionnaire score and lung total blood vessel volume (in milliliters), measured by chest Computed Tomography.
- Correlation between University of California, San Diego
Shortness of Breath Questionnaire score and lung total airway count. [ Time Frame: Baseline and one year ]
Correlation coefficient between University of California, San Diego Shortness of Breath Questionnaire score and lung total airway count, measured by chest Computed Tomography.
- Correlation between University of California, San Diego Shortness of Breath Questionnaire score and lung low attenuation areas. [ Time Frame: Baseline and one
year ]
Correlation coefficient between University of California, San Diego Shortness of Breath Questionnaire score and lung low attenuation areas, measured by chest Computed Tomography.
- Correlation between University of California, San Diego Shortness of Breath Questionnaire score and lung total water content. [ Time Frame: Baseline and one year ]
Correlation coefficient between University of California, San Diego Shortness of Breath Questionnaire score and lung total water content (in arbitrary units), measured by proton Magnetic Resonance Imaging.
- One year changes in lung total blood vessel volume. [ Time Frame: Baseline and one year ]
Comparison of lung total blood vessel volume (in milliliters) at one year versus baseline, measured by chest Computed Tomography.
- One year changes in lung total airway count. [ Time Frame: Baseline and one year ]
Comparison of lung total airway count at one year versus baseline, measured by chest Computed Tomography.
- One year changes in lung water content. [ Time Frame: Baseline and one year ]
Comparison of lung water content (in arbitrary units) at one year versus baseline, measured by proton Magnetic Resonance Imaging.
- One year changes in lung low attenuation areas. [ Time Frame: Baseline and one year ]
Comparison of lung low attenuation areas at one year versus baseline, measured by chest Computed Tomography.
- One year changes in pulmonary artery diameter. [ Time Frame: Baseline and one year ]
Comparison of pulmonary artery diameter (in millimeters) at one year versus baseline, measured by chest Computed Tomography.
- Baseline pulmonary artery systolic pressure. [ Time Frame: Baseline ]
Baseline pulmonary artery systolic pressure (in mmHg), measured by transthoracic doppler echocardiography.
- One year changes in pulmonary artery systolic pressure. [ Time Frame: Baseline and one year ]
Comparison of pulmonary artery systolic pressure in mmHg at one year versus baseline, measured by transthoracic doppler echocardiography.
- Baseline fractional exhaled nitric oxide. [ Time Frame: Baseline ]
Baseline fractional exhaled nitric oxide measured (in parts per billion).
- One year changes in fractional exhaled nitric oxide. [ Time Frame: Baseline and one year ]
Comparison of fractional exhaled nitric oxide measured (in parts per billion) at one year versus baseline.
- Baseline forced expiratory volume at one second/forced vital capacity ratio. [ Time Frame: Baseline ]
Baseline forced expiratory volume at one second/forced vital capacity ratio by pulmonary function tests.
- One year
changes in forced expiratory volume at one second/forced vital capacity ratio. [ Time Frame: Baseline and one year ]
Comparison of forced expiratory volume at one second/forced vital capacity ratio at one year versus baseline, by pulmonary function tests.
- Baseline diffusing capacity of the lung for carbon monoxide. [ Time Frame: Baseline ]
Baseline diffusing capacity of the lung for carbon monoxide (in ml/min/kPa), by pulmonary function tests.
- One year changes in diffusing capacity of the lung for carbon monoxide. [ Time Frame: Baseline and one year ]
Comparison of diffusing capacity of the lung for carbon monoxide (in ml/min/kPa) at one year versus baseline, by pulmonary function tests
- Baseline six minute walk distance. [ Time Frame: Baseline ]
Baseline six minute walk distance (in meters) measured by six minute walk test.
- One year
changes in six minute walk distance. [ Time Frame: Baseline and one year ]
Comparison of six minute walk distance (in meters) at one year versus baseline, measured by six minute walk test.
- One year changes in soft tissue sodium content. [ Time Frame: Baseline and one year ]
Comparison of soft tissue sodium content (in mmol/L) at one year versus baseline, measured by sodium Magnetic Resonance Imaging.
Biospecimen Retention: Samples Without DNA
Plasma and serum.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The patients for this trial will be recruited from incident and prevalent hemodialysis patients receiving care for their kidney disease from the Dialysis Service at London Health Sciences Centre, London Ontario. Up to 20 eligible patients will be recruited.
Inclusion Criteria:
- Age equal to or greater than 18 years.
- Dialysis vintage equal to or greater than 3 months.
Exclusion Criteria
- Smoking history of more than 10 packs/year.
- Active tobacco and/or cannabis smoking.
- Diagnosed chronic pulmonary disease.
- Severe heart failure (NYHA class IV)
- Active infection (including tuberculosis) or malignancy.
- Pregnancy.
- Inability to give consent or understand written information.
- Peripheral oxygen saturation (by pulse oxymetry) dropping below 80% when performing a 12-seconds breathhold.
- Inability to perform spirometry or plethysmography maneuvers.
- Inability to tolerate MRI due to patient size and/or known history of claustrophobia.
- Subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants.).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773991
Layout table for location information
Canada, Ontario | |
London Health Sciences Centre | |
London, Ontario, Canada |
Lawson Health Research Institute
University of Western Ontario, Canada
Western University, Canada
Layout table for investigator information
Principal Investigator: | Christopher W McIntyre, MD PhD | Lawson Health Research Institute |
Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, Lindholm B, Parati G, Sicari R, Gargani L, Mallamaci F, London G, Zoccali C. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013 Apr;61(4):612-22. doi: 10.1053/j.ajkd.2012.07.029. Epub 2012 Nov 17. Review. Erratum in: Am J Kidney Dis. 2015 Mar;65(3):524.
Plesner LL, Warming PE, Nielsen TL, Dalsgaard M, Schou M, Høst U, Rydahl C, Brandi L, Køber L, Vestbo J, Iversen K. Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis. Hemodial Int. 2016 Jan;20(1):68-77. doi: 10.1111/hdi.12342. Epub 2015 Aug 5.
Layout table for additonal information
Responsible Party: | Chris McIntyre, Professor of Medicine, Medical Biophysics and Paediatrics, University of Western Ontario. Director of The Lilibeth Caberto Kidney Clinical Research Unit, London Health Sciences Centre., Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT03773991 |
Other Study ID Numbers: | 110256 |
First Posted: | December 12, 2018 Key Record Dates |
Last Update Posted: | November 16, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Chris McIntyre, Lawson Health Research Institute:
Dyspnea Hemodialysis End Stage Renal Disease |
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases Dyspnea Kidney Diseases Kidney Failure, Chronic Heart Diseases Cardiovascular Diseases Respiratory Tract Diseases Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency Respiration Disorders Signs and Symptoms, Respiratory Nitric Oxide Bronchodilator Agents | Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents |